Keystone Nano
{{Orphan|date=August 2016}}
{{Refimprove|date=August 2015}}
Keystone Nano, founded in 2005, is an American-based company based in Pennsylvania, that creates nanoscale products to diagnose and treat human disease and improve the quality of life.{{cite web|title=Company Overview of Keystone Nano, Inc.|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=59073403|website=Bloomberg|accessdate=10 August 2015}}
Patents
Keystone Nano Inc. and team has been granted the follow patents:
- US Patent (8,747,891) - Awarded to The Penn State Research Foundation and Keystone Nano's Chief Medical Officer Mark Kester, this patent describes the process of loading Ceramide nano-scale liposomes with anti-cancer compounds and create a combination of therapies that benefit from the therapeutic activity of both Ceramide and the anti-cancer compound. This process improves the delivery of both compounds by targeting tumors and extending the time of biological activity.{{cite web|title=Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes|url=http://www.nanotech-now.com/news.cgi?story_id=51035|website=Nanotechnology Now|accessdate=9 August 2015}}{{cite web|last1=Falce |first1=Lori |title=Local firm builds on Penn State patent to fight cancer |url=http://www.centredaily.com/2015/03/12/4648362_local-firm-builds-on-penn-state.html?rh=1 |website=Centre Daily Times |accessdate=10 August 2015 |url-status=dead |archiveurl=https://web.archive.org/web/20150923202031/http://www.centredaily.com/2015/03/12/4648362_local-firm-builds-on-penn-state.html?rh=1 |archivedate=23 September 2015 }}
FDA Approval
In January 2017, the FDA approved the investigational new drug application, NanoLiposome, to assess the product as a form of treatment for solid tumors. Phase 1 trials will take place at the University of Maryland, University of Virginia, and the Medical University of South Carolina.{{cite web|title=FDA Approves Investigational New Drug Application for Ceramide NanoLiposome|url=http://www.pharmacytimes.com/product-news/fda-approves-investigational-new-drug-application-for-ceramide-nanoliposome|website=Pharmacy Times|accessdate=14 January 2017}}{{Dead link|date=June 2025 |bot=InternetArchiveBot |fix-attempted=yes }}
Compound
Keystone was approved in 2017 to begin clinical trials to assess ceramide nanoliposome for possible use in treating cancer.{{cite web|title=Investigational cancer compound receives FDA approval to begin human trials|url=http://news.psu.edu/story/473555/2017/06/29/research/investigational-cancer-compound-receives-fda-approval-begin-human|website=Penn State News}}
References
{{reflist}}